Agronomics, Liberation Labs에 천만 달러 투자
5th 4월 2024
농업 경제학 제한
("농업" 또는 "회사")
Agronomics Invests US$ 10 million in Liberation Labs
Agronomics (LSE: ANIC), a leading listed company focused on the field of cellular agriculture, is pleased to announce that it has invested US$ 10 million in its portfolio company Liberation Labs Holding Inc. ("Liberation Labs") as part of a wider US$ 12.5 million financing round with participation from existing investor Siddhi Capital. The investment was made in the form of a Secured Convertible Promissory Note ("SCPN"), a form of convertible debt, for the continued construction of its facility in Richmond, Indiana in advance of Liberation Labs' Series A round (a "Qualified Financing"). The SCPN will convert into the same instrument and terms as the Qualified Financing which is anticipated to raise a minimum of US$ 37.5 million through a combination of debt and equity. The investment was made using cash from the Company's own resources.
Including this SCPN, Liberation Labs has now raised US$ 33.5 million in equity-linked instruments and has formal commitments for non-dilutive funding totalling a further US$ 55 million. This includes US$ 30 million in equipment financing and a US$ 25 million loan from Ameris Bank which is backed by the U.S. Department of Agriculture via the Business and Industry Guaranteed Loan Program.
Liberation Labs is seeking to become the industrial biotechnology industry's global fabrication partner through the design, build and operation of Bio3, its purpose-built biomanufacturing platform. This platform will address the critical bottleneck which fermentation companies face. Liberation Labs broke ground in June 2023 on its first facility which when complete will have 600k litres of fermentation capacity. Today, the project is approximately halfway through its build programme and, subject to completion of the Qualified Financing, is expected to be commissioned in Q1 2025. This site, located in Richmond, Indiana which has the potential to be expanded by an additional 4 million litres of capacity was selected considering several key metrics such as access to sugar inputs, utility rates, cost and availability of labour, regulatory environment, availability of government incentives.
Including the SCPN, Agronomics has invested US$ 17.6 million in Liberation Labs which, subject to audit, is currently carried at a book value of £25.7 million. This position represents approximately 14.8% of Agronomics' last stated Net Asset Value, including post-balance sheet date adjustments. Agronomics now holds 37.5% of Liberation Labs on a fully diluted basis.
Mark Warner, CEO and Co-Founder of Liberation Labs said:
"The new funding from Agronomics and Siddhi Capital comes as we continue to make significant progress in building out our operations team and advancing facility construction - including the installation of key equipment like fermenters and spray dryers. Each day we're closer to our goal of unlocking the potential of domestic manufacturing of novel proteins for both food and industrial use. We greatly appreciate the continued support of our major funding partners."
Jim Mellon, Executive Chairman of Agronomics added:
"Liberation Labs continues to deliver on the project milestones of its launch facility in Indiana. We have huge confidence in the team's ability to execute and believe that Liberation Labs will become the first company in Agronomics' portfolio to be cash generative."
About Liberation Labs
Liberation Labs is commercializing precision fermentation with a global network of purpose-built manufacturing facilities that enable the next wave of biotechnology advancements to produce bio-based consumer products at scale. We combine modern technology with fit-for-purpose design to bring reliable and cost-effective solutions that meet customer demand across the world. More information is available at www.liberationlabs.com.
농업 학 제한된 | 버몬트 코니쉬 리미티드 | Canaccord 제뉴이티 리미티드 | 캐번디시 캐피털 마켓 리미티드 | 피터하우스 캐피탈 제한된 | 삼성전자 뉴게이트 |
Storets | 유목민 | 관절 Broker | 관절 Broker | 관절 Broker | 홍보영상제작 |
짐 멜론 덴햄 에크 | 롤랜드 코니쉬 제임스 비들 | 앤드류 포츠 해리 팔도 알렉스 아일렌 | 자일스 발레니 마이클 존슨 찰리 빗 | 루시 윌리엄스 찰스 굿펠로우 | 밥 헉스포드 |
+44 (0) 1624 639396 | + 44 (0) 207 628 3396 | + 44 (0) 207 523 8000 | + 44 (0) 207 397 8900 | + 44 (0) 207 469 0936 |
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.